Previous 10 | Next 10 |
MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients...
MENLO PARK, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients...
MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients...
MENLO PARK, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced ...
2023-09-20 11:55:57 ET More on Health Care Sector: Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutiv...
2023-09-12 17:41:30 ET More on Sight Sciences Seeking Alpha’s Quant Rating on Sight Sciences Historical earnings data for Sight Sciences Financial information for Sight Sciences Sight Sciences: Staying Bullish After Q2 Results Beat Sight Scienc...
2023-09-12 12:52:44 ET Gainers: Anebulo Pharmaceuticals ( ANEB ) +35% . WeWork ( WE ) +34% . Shengfeng Development Limited ( SFWL ) +29% . AEON Biopharma ( AEON ) +28% . Avalo Therapeutics ( AVTX ) +28% . The Beauty Health Co...
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Sight Sciences, Inc. (“Sight Sciences” or “the Company”) (NASDAQ: SGHT) complied with federal securities laws. On September 11, 2023, Sight Sciences announced its third quarte...
2023-09-12 08:42:44 ET Losers: Acelyrin ( SLRN ) -56% announces top-line results from placebo-controlled clinical trial of Izokibep for moderate-to-severe Hidradenitis Suppurativa. Sight Sciences ( SGHT ) -31% on updated guidance . Super League Gaming (...
2023-09-12 06:14:55 ET Related stories Compare metrics for HUMA to ORCL, SGHT, SLRN, WRK WestRock: Solid Asset-Based, But (Likely) Not The Right Time Reevaluating Acelyrin: The Impact Of Mixed Izokibep Results (Rating Downgrade) Oracle Corporation ( ORCL ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-17 00:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of ...
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform car...